BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35100741)

  • 1. Circulating Tumor DNA Profiling of Advanced Biliary Tract Cancers.
    Mody K; Kasi PM; Yang J; Surapaneni PK; Bekaii-Saab T; Ahn DH; Mahipal A; Sonbol MB; Starr JS; Roberts A; Nagy R; Lanman R; Borad MJ
    JCO Precis Oncol; 2019 Dec; 3():1-9. PubMed ID: 35100741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma.
    Botrus G; Kosirorek H; Sonbol MB; Kusne Y; Uson Junior PLS; Borad MJ; Ahn DH; Kasi PM; Drusbosky LM; Dada H; Surapaneni PK; Starr J; Ritter A; McMillan J; Wylie N; Mody K; Bekaii-Saab TS
    Oncologist; 2021 Jul; 26(7):569-578. PubMed ID: 33555095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility of circulating tumor DNA testing in hepatocellular carcinoma.
    Mody K; Kasi PM; Yang JD; Surapaneni PK; Ritter A; Roberts A; Nagy R; Borad MJ
    J Gastrointest Oncol; 2019 Aug; 10(4):745-750. PubMed ID: 31392055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer.
    Berchuck JE; Facchinetti F; DiToro DF; Baiev I; Majeed U; Reyes S; Chen C; Zhang K; Sharman R; Uson Junior PLS; Maurer J; Shroff RT; Pritchard CC; Wu MJ; Catenacci DVT; Javle M; Friboulet L; Hollebecque A; Bardeesy N; Zhu AX; Lennerz JK; Tan B; Borad M; Parikh AR; Kiedrowski LA; Kelley RK; Mody K; Juric D; Goyal L
    Ann Oncol; 2022 Dec; 33(12):1269-1283. PubMed ID: 36089135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Profiling in Daily Clinical Practice: Practicalities in Advanced Cholangiocarcinoma and Other Biliary Tract Cancers.
    Lamarca A; Kapacee Z; Breeze M; Bell C; Belcher D; Staiger H; Taylor C; McNamara MG; Hubner RA; Valle JW
    J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32899345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study.
    Rizzato M; Brignola S; Munari G; Gatti M; Dadduzio V; Borga C; Bergamo F; Pellino A; Angerilli V; Mescoli C; Guido M; Rearden J; Gringeri E; Cillo U; Dei Tos AP; Zagonel V; Loupakis F; Lonardi S; Fassan M
    Eur J Cancer; 2022 May; 166():165-175. PubMed ID: 35303508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular profiling of biliary tract cancers reveals distinct genomic landscapes between circulating and tissue tumor DNA.
    Astier C; Ngo C; Colmet-Daage L; Marty V; Bawa O; Nicotra C; Ngo-Camus M; Italiano A; Massard C; Scoazec JY; Smolenschi C; Ducreux M; Hollebecque A; Postel-Vinay S
    Exp Hematol Oncol; 2024 Jan; 13(1):2. PubMed ID: 38191492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood-Based Next-Generation Sequencing Analysis of Appendiceal Cancers.
    Shaib WL; Zakka K; Staley C; Roberts A; Akce M; Wu C; Alese OB; El-Rayes BF
    Oncologist; 2020 May; 25(5):414-421. PubMed ID: 31784493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Molecular Landscape of Pancreatobiliary Cancers for Novel Targeted Therapies From Real-World Genomic Profiling.
    Umemoto K; Yamamoto H; Oikawa R; Takeda H; Doi A; Horie Y; Arai H; Ogura T; Mizukami T; Izawa N; Moore JA; Sokol ES; Sunakawa Y
    J Natl Cancer Inst; 2022 Sep; 114(9):1279-1286. PubMed ID: 35583261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA-Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis.
    Kim ST; Banks KC; Lee SH; Kim K; Park JO; Park SH; Park YS; Lim HY; Kang WK; Lanman RB; Talasaz A; Park K; Lee J
    JCO Precis Oncol; 2017; 1():. PubMed ID: 32913970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Not Available].
    Valéry M; Cervantes B; Smolenschi C; Boige V; Ducreux M; Cohen R; Hollebecque A
    Bull Cancer; 2022 Nov; 109(11S):11S21-11S27. PubMed ID: 36535759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targetable Molecular Alterations in the Treatment of Biliary Tract Cancers: An Overview of the Available Treatments.
    Valery M; Vasseur D; Fachinetti F; Boilève A; Smolenschi C; Tarabay A; Antoun L; Perret A; Fuerea A; Pudlarz T; Boige V; Hollebecque A; Ducreux M
    Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Advanced Biliary Tract Cancer.
    Chen C; Wang T; Yang M; Song J; Huang M; Bai Y; Su H
    Pathol Oncol Res; 2021; 27():1609879. PubMed ID: 34720757
    [No Abstract]   [Full Text] [Related]  

  • 14. Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer.
    Ledet EM; Lilly MB; Sonpavde G; Lin E; Nussenzveig RH; Barata PC; Yandell M; Nagy RJ; Kiedrowski L; Agarwal N; Sartor O
    Oncologist; 2020 Apr; 25(4):327-333. PubMed ID: 32297439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus.
    Schrock AB; Pavlick D; Klempner SJ; Chung JH; Forcier B; Welsh A; Young L; Leyland-Jones B; Bordoni R; Carvajal RD; Chao J; Kurzrock R; Sicklick JK; Ross JS; Stephens PJ; Devoe C; Braiteh F; Ali SM; Miller VA
    Clin Cancer Res; 2018 Apr; 24(8):1881-1890. PubMed ID: 29363525
    [No Abstract]   [Full Text] [Related]  

  • 16. Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics.
    Choi IS; Kato S; Fanta PT; Leichman L; Okamura R; Raymond VM; Lanman RB; Lippman SM; Kurzrock R
    Mol Cancer Ther; 2019 Oct; 18(10):1852-1862. PubMed ID: 31320401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer.
    Gupta R; Othman T; Chen C; Sandhu J; Ouyang C; Fakih M
    Oncologist; 2020 Mar; 25(3):235-243. PubMed ID: 32162812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of comprehensive cancer genomic profiling on therapeutic strategies and clinical outcomes in patients with advanced biliary tract cancer: A prospective multicenter study.
    Takada K; Kubo T; Kikuchi J; Yoshida M; Murota A; Arihara Y; Nakamura H; Nagashima H; Tanabe H; Sugita S; Tanaka Y; Miura A; Ohhara Y; Ishiguro A; Yokouchi H; Kawamoto Y; Mizukami Y; Ohnishi H; Kinoshita I; Sakurai A
    Front Oncol; 2022; 12():988527. PubMed ID: 36119486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma.
    Kato S; Okamura R; Baumgartner JM; Patel H; Leichman L; Kelly K; Sicklick JK; Fanta PT; Lippman SM; Kurzrock R
    Clin Cancer Res; 2018 Dec; 24(24):6248-6256. PubMed ID: 30348637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsy.
    Li G; Pavlick D; Chung JH; Bauer T; Tan BA; Peguero J; Ward P; Kallab A; Bufill J; Hoffman A; Sadiq A; Edenfield J; He J; Cooke M; Hughes J; Forcier B; Nahas M; Stephens P; Ali SM; Schrock AB; Ross JS; Miller VA; Gregg JP
    J Gastrointest Oncol; 2019 Oct; 10(5):831-840. PubMed ID: 31602320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.